Dechra sets its sights on two major deals and South Korean subsidiary

FTSE 100-listed Dechra posted a 13.8 per cent rise in revenue to £681.8million for the year to 30 June, up from £608million a year ago.

Related Keywords

California ,United States ,South Korea ,Piedmont ,South Korean ,America ,Max Herrmann ,Ian Page ,Adam Vettese ,Dechra Pharmaceuticals ,Piedmont Animal Health ,Interactive Investor ,Dechra Pharmaceutical ,While Dechra ,Thisismoney ,Money ,Moneymarkets ,